Mainland hospitals experienced persistent and potentially heightened reimbursement pressure during the first half of the year, with no obvious signs of reversal. Within the self-pay medical segment, vision correction surgery volumes slowed during the peak summer season, while medical aesthetics growth largely met expectations. Hospitals reliant on public insurance reimbursement continued confronting pricing pressure throughout H1, despite policy-driven improvements in accounts receivable collection. Consumer healthcare services, such as vision correction procedures, showed renewed deceleration in Q2 after strong Q1 performance, partly due to pent-up treatment demand. JXR (01951) was downgraded to Underweight due to enduring pressures across its mainland and overseas facilities. CR MEDICAL (01515), HYGEIA HEALTH (06078), and to a lesser extent Aier Eye Hospital (300015.SZ) are expected to face profit headwinds. Conversely, robust demand for medical aesthetics and beauty treatments should support BEAUTYFARM MED's (02373) profit growth aligning with projections.